News

Overheard in Boston: Medtech CEOs talk rising costs, turbulent markets, cyberattacks

At AdvaMed’s The MedTech Conference, CEOs from top medical device companies shared how they navigate difficult times, inflation and new technologies.

Yahoo·10:24BSX▼−1.5%

Boston Scientific to participate in Stifel's 2026 Healthcare Conference

Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2026 Healthcare Conference on Wednesday, November 11, 2026. Kenneth Stein, M.D., senior vice president and global chief medical officer, and Lance Bates, executive vice president and president, Interventional Cardiology & Vascular Therapies, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.

Yahoo·08:00BSX▼−1.5%

Stifel Maintains Buy on Boston Scientific, Lowers Price Target to $55

Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $55.

Benzinga·07:25BSX▼−1.5%

Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

Yahoo·08:15BSX▼−1.5%

Boston Scientific (BSX) Stock May Be 44% Undervalued As Neuromodulation Growth Builds

Boston Scientific has seen its share price fall sharply over the past year, even as the business pushes deeper into higher end medical devices like neuromodulation. That slide raises a simple question for you as an investor: does the current valuation still line up with the cash the company is expected to generate over time? The stock is down 57.1% over the past year, which puts the focus firmly on whether the recent share price now fully reflects its cash flow profile. Boston Scientific's...

Yahoo·15:15BSX▼−1.5%

Can Boston Scientific Stock Jump 30%?

For questions about this article or underlying research, email help@trefis.com.

Yahoo·07:45BSX▼1.5%

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

Boston Scientific (BSX) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day.

Yahoo·17:00BSX▼−1.5%

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00BSX▼−1.5%

BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?

Boston Scientific's Q3 results hinge on MedSurg strength in Endoscopy and Neuromodulation, as Cardiovascular faces competitive pressures and softer sales.

Yahoo·08:26BSX▼−1.5%

Should Becton Dickinson Stock Holders Look At Boston Scientific Instead?

Investors hold Becton Dickinson (BDX) and Boston Scientific (BSX) for newer products that grow faster than the rest of their sales. Becton Dickinson sells everyday hospital supplies such as syringes, with faster-growing lines that include PureWick and biologic drug delivery. Boston Scientific sells cardiology devices such as WATCHMAN. Boston Scientific stock trades at 18.0 times earnings, compared with 55.7 for Becton Dickinson. You gain from that lower price only if the slowdown in WATCHMAN end

Yahoo·19:05BSX▼−1.5%

Boston Scientific: A Better Valuation, But The Turnaround Needs Proof

SeekingAlpha·11:46BSX▼−1.5%

Boston Scientific (BSX) Rises Higher Than Market: Key Facts

Boston Scientific (BSX) closed at $44.14 in the latest trading session, marking a +2.65% move from the prior day.

Yahoo·17:00BSX▼−1.5%

Is Boston Scientific Stock Riskier Than It Was A Year Ago?

Investors in Boston Scientific (BSX) hold stakes in a medical device maker that grew revenue 13.5% over the twelve months to June 2026. Yet the shares have lost 54.7% over the past year, trailing a 17.3% gain for the S&P 500. In August, a cyberattack disrupted the company's manufacturing and order shipments. So has the risk in holding Boston Scientific shares gone up or down over the past year.

Yahoo·15:18BSX▼−1.5%

Boston Scientific (BSX) Recalls 262,686 Catheters Over Life Threatening Tip Failure Risk

Boston Scientific (NYSE: BSX) has begun a voluntary worldwide recall of its Imager II Angiographic Catheters due to catheter tip issues. The recall follows reports that the catheter tip may fracture or detach during use, with potential life threatening patient complications. The action covers Imager II devices used in cardiovascular procedures across multiple international markets, affecting current inventories in hospitals and clinics. This catheter recall is only one part of the Boston...

Yahoo·19:20BSX▼−1.5%

What Could BSX Stock Be Worth In Three Years?

Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends, excluding readings above a hundred. Investors evaluating the stock must look ahead to model potential returns. So what might a share bought at $43.31 be worth three years from now.

Yahoo·16:55

Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.

Benzinga·09:28BSX▼−1.5%

Earnings Preview: What to Expect From Boston Scientific’s Report

Boston Scientific will unveil its fiscal third-quarter results by the end of this month, and analysts forecast a single-digit uptick in its bottom line.

Yahoo·07:45BSX▼−1.5%

Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.

Yahoo·08:00BSX▼−1.5%

Boston Scientific names Joseph Fitzgerald as chief operating officer

Fitzgerald will oversee three newly established reportable segments as Boston Scientific works to bounce back from guidance cuts.

Yahoo·06:55BSX▼−1.5%

1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Yahoo·04:08

Why Is Boston Scientific (BSX) Reorganizing Into Three Segments Under A New COO?

Boston Scientific (NYSE: BSX) appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027. The company plans to reorganize its global operations into three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg. Fitzgerald is expected to oversee the transition to the new segment structure as part of a broader operational realignment. The leadership change and shift to Interventional Therapies, Rhythm Solutions, and...

Yahoo·00:29BSX▼−1.5%

Barclays Initiates Coverage of Boston Scientific with Equal-Weight

Fintel·19:58BSX▼−1.5%

Intel downgraded, Marvell upgraded: Wall Street's top analyst calls

Intel downgraded, Marvell upgraded: Wall Street's top analyst calls

Yahoo·10:00

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company's global operations, business units and regions.

Yahoo·06:00BSX▼−1.5%

Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48

Barclays analyst Christopher Pasquale initiates coverage on Boston Scientific (NYSE:BSX) with a Equal-Weight rating and announces Price Target of $48.

Benzinga·04:18BSX▼−1.5%

Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $50 to $48.

Benzinga·04:27BSX▼−1.5%

Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know

In the closing of the recent trading day, Boston Scientific (BSX) stood at $44.92, denoting a +2.74% move from the preceding trading day.

Yahoo·18:00BSX▼−1.5%

Ammonix Launches a New AI Architecture for High-Stakes Specialist Agents That Outperform Frontier Models at a Lower Cost

Ammonix today emerged from stealth with a new AI architecture that combines a fast, specialized System One decision-making architecture with a System Two language model for reasoning and interaction.

Yahoo·09:00

Cordis wins FDA approval for sirolimus-eluting balloon

The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.

Yahoo·05:56BSX▼−1.5%

2 Value Stocks with Exciting Potential and 1 We Avoid

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Yahoo·05:25

Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?

BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.

Yahoo·09:10BSX▼−1.5%

New Strong Sell Stocks for September 21st

AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.

Yahoo·06:45BSX▼−1.5%

Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.

Benzinga·05:48BSX▼−1.5%

Boston Scientific (BSX) Stock Trades At A Discount On A 55% Slump

Boston Scientific has seen its share price fall sharply over the past year, which naturally raises a question for investors who care about fundamentals. Are the cash flows that the business can generate enough to support where the stock trades today, or has sentiment moved further than the underlying economics justify? The share price has declined 55.4% over the past year, so the recent slide puts the focus squarely on whether that move lines up with the cash that Boston Scientific can...

Yahoo·13:09BSX▼−1.5%

BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.

Yahoo·09:07BSX1.5%

1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Challenges

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Yahoo·08:41

BSX Stock: Is It Time To Buy Or Sell Puts?

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

Yahoo·14:06BSX▼−1.5%

2 Healthcare Stocks with Competitive Advantages and 1 We Question

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 25.7% over the past six months while the S&P 500 was up 13.6%.

Yahoo·10:34

Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

Yahoo·09:12

Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.

Benzinga·05:04BSX▼−1.5%

BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $56

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $56.

Benzinga·03:22BSX▼−1.5%

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th

Yahoo·15:48

ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine

Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.

Yahoo·11:51

Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?

iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.

Yahoo·11:12

Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

Yahoo·10:27BSX▼−1.5%

Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk

Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.

Benzinga·08:43BSX▼−1.5%

Boston Scientific begins to restore shipping after cyberattack

The company is working through a backlog after the cyberattack hampered manufacturing, order processing and shipping.

Yahoo·07:30BSX▼−1.5%

Did Recalls And Cyberattack Disruptions Just Shift Boston Scientific's (BSX) Investment Narrative?

In recent weeks, Boston Scientific has faced multiple voluntary global recalls of its Suture Cinch endoscopic devices and ENROUTE Transcarotid Neuroprotection systems, alongside a cybersecurity incident that disrupted operations and led to reduced full‑year 2026 sales and earnings guidance. These simultaneous product quality issues, operational disruptions, and softer demand for key franchises raise fresh questions about the resilience of Boston Scientific’s previously growth-focused...

Yahoo·05:21BSX▼−1.5%

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.

Yahoo·18:00BSX▼−1.5%

1 Stock Under $50 to Target This Week and 2 We Ignore

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Yahoo·17:20

2 Reasons to Watch BSX and 1 to Stay Cautious

Boston Scientific has gotten torched over the last six months - since March 2026, its stock price has dropped 36.9% to $48.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.

Yahoo·12:24BSX▼−1.5%

How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?

Despite Boston Scientific’s weak performance relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects

Yahoo·10:23BSX▼−1.5%

The Peer-Group Mispricing Sitting On BSX Stock

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

Yahoo·21:47BSX▼−1.5%

Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·12:30BSX▼−1.5%

Are You Still Holding Boston Scientific Stock For Its Next Device?

Its capital budget has overtaken its research budget for the first time in the fifteen years on record, and two of the seven launches management is counting on to restore growth come from outside its own labs.

Yahoo·15:45BSX▼−1.5%

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Benzinga·09:35

Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device Franchises

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

Yahoo·16:48BSX▼−1.5%

If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.54% on an annualized basis producing an average annual return of 15.01%. Currently, Boston Scientific has a market capitalization of

Benzinga·07:01BSX1.5%

Boston Scientific (BSX), What Is Behind The Latest Investor Attention?

Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2.0b. The completed buyback represents 2.69% of the company’s shares. This update provides an additional data point on how Boston Scientific is allocating capital and managing its share count. It also offers a clearer backdrop for assessing recent stock performance and earnings expectations. See...

Yahoo·01:08BSX▼−1.5%